Key facts
- This page summarizes Michael Grissinger's Form 4 filing for Akari Therapeutics Plc (AKTX).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 02 Jul 2024, 16:30.
Michael Grissinger - 28 Jun 2024 Form 4 Insider Report for Akari Therapeutics Plc (AKTX)
- Reporting relationship
- Director
- Issuer ticker
- AKTX
- Reported as of
- 28 Jun 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 02 Jul 2024, 16:30:11 UTC
- Prior SEC filing
- 21 Jun 2024
- Next SEC filing
- 21 Apr 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Wendy F. DiCicco, as Attorney-in-Fact for Michael Grissinger
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Michael Grissinger filed Form 4 for Akari Therapeutics Plc (AKTX) on 02 Jul 2024.
Change
- Previous filing in this sequence was filed on 21 Jun 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
AKTX
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +5,000,000
- Change %
- Price
- $0.000000
- Shares after
- 5,000,000
- Date
- 28 Jun 2024
- Ownership
- Direct
- Underlying class
- Ordinary Shares, par value $0.0001 per share
- Underlying amount
- 5,000,000
- Exercise price
- $0.001400
- Footnotes
- F1, F2, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
The stock options have an exercise price of $0.001395 per ordinary share, par value $0.0001 per share ("Ordinary Share").
Footnote F2
Non-qualified stock option granted under the Issuer's 2023 Equity Incentive Plan. One-hundred percent (100%) of the stock option vests and becomes exercisable on the date of the Issuer's 2025 Annual General Meeting of Shareholders, subject to continued service with the Issuer.
Footnote F3
The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents 2,000 Ordinary Shares.
SEC remarks
See Exhibit 24.1 - Power of Attorney